Special Issue

Glomerulonephritis: Pathogenesis, Risk Factors, and Treatment

Message from the Guest Editor

Dear Colleagues Glomerulonephritis, one of the leading causes of end-stage renal disease, is a group of rare diseases with different presentations, clinical courses, and outcomes. The main causes of chronic kidney disease are hypertension and diabetes, which mainly affect adulthood. However, there are several chronic glomerulonephritis types or idiopathic or secondary to autoimmune diseases that instead begin in adolescent or juvenile age. Kidney biopsy remains the cornerstone for the evaluation of these glomerular diseases. In recent years, clinical and laboratory research has made significant contributions to the understanding of the pathogenesis of glomerulonephritis that is however still uncertain and not completely understood. Current treatment is based on the use of corticosteroids and immunosuppressive drugs. These drugs, which have improved the course of these chronic glomerulonephritis diseases, are however toxic and have many side effects. Recent pathogenetic knowledge has determined the development of a new therapy, especially biological drugs, with excellent efficacy and few side effects.

Guest Editor

Dr. Giovanni Conti

Pediatric Nephrology Unit, AOU Policlinic "G Martino", University of Messina, 98125 Messina, Italy

Deadline for manuscript submissions

closed (31 July 2021)



Medicina

an Open Access Journal Published by MDPI

Impact Factor 2.4 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/39798

Medicina
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicina@mdpi.com

mdpi.com/journal/ medicina





Medicina

an Open Access Journal Published by MDPI

Impact Factor 2.4 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius

Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

